Recent developments include financial results reporting, significant financing, acquisitions, regulatory approvals, and joint ventures advancing the company’s cardiac electrophysiology product portfolio and business strategy.

• Catheter Precision reported Q3 2024 financial results highlighting revenue growth in LockeT and ongoing operational activities [N1].
• The company secured $88 million in financing to support growth in its aviation and medical businesses [N2].
• Catheter Precision acquired Fly Flyte from Creatd, expanding its business scope [N3].
• LockeT wound closure device received UK approval, leading to a share price increase of over 65% [N4].
• Catheter Precision and Chelak iECG launched the KardioNav joint venture to advance ventricular tachycardia ablation technology [N5].
• The company addressed increased trading activity in its common stock [N6].
• Catheter Precision secured its first order for the VIVO product from Sahlgrenska University Hospital in Sweden [N7].
• LockeT received CE Mark approval, expanding market opportunities in Europe [N8].

Catheter Precision has developed FDA-cleared and CE-marked products with clinical evidence supporting their safety and efficacy, including over 1,000 VIVO procedures and positive LockeT study results. The company’s strategy to expand indications and improve product usability, including development of VIVO generation 3, could enhance clinical adoption. Its subsidiaries Cardionomix and KardioNav pursue innovative cardiac technologies that may complement the core product portfolio. Long-term contracts with hospitals for LockeT and international distributor agreements support revenue growth potential. The company’s focus on reducing procedure time, patient complications, and costs aligns with healthcare provider priorities.

The company faces significant liquidity constraints with a current ratio of 0.1 and cash on hand insufficient to fund operations beyond the near term without additional financing. It has incurred substantial net losses and negative cash flows since inception, raising substantial doubt about its ability to continue as a going concern. The competitive landscape includes large medical device companies with greater resources. Market adoption of its products may be limited by sales force changes and reduced efforts in key regions. Clinical development of acquired assets depends on securing dedicated financing. Failure to raise capital or achieve profitable operations could impair business continuity.

Catheter Precision's moat is based on its proprietary non-invasive cardiac mapping technology (VIVO System) with FDA and CE regulatory clearances, supported by clinical data demonstrating accuracy and procedural benefits. Its LockeT device offers a differentiated wound closure solution with regulatory approvals and clinical validation. The company’s intellectual property portfolio includes patents for these technologies and acquired assets. Its specialized focus on ventricular arrhythmia mapping and wound closure addresses underserved clinical needs. However, the company operates in a highly competitive medical device market with large established players possessing greater resources, which challenges its market penetration and scale.

• Liquidity and Going Concern Risk: The company has limited cash and current assets relative to current liabilities, with substantial doubt about its ability to continue as a going concern without additional financing.
• Competitive Risk: Catheter Precision operates in a highly competitive medical device market with large established companies that have greater financial and marketing resources.
• Regulatory and Clinical Development Risk: The company’s products and acquired technologies require regulatory approvals and successful clinical development, which may be costly and uncertain.
• Market Adoption Risk: Sales efforts have been impacted by leadership changes and medical leave, particularly in the EU, potentially limiting product adoption and revenue growth.
• Financing and Dilution Risk: The company may need to raise additional capital on terms that could dilute existing shareholders and may not be available on favorable terms or at all.

• Catheter Precision, Inc. focuses on the design, manufacture, and sale of medical technologies in cardiac electrophysiology (EP).
• The company’s two primary products are the VIVO System and LockeT device.
• The VIVO System is a non-invasive 3D cardiac mapping system to localize idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures.
• VIVO has FDA 510(k) clearance in the U.S. and CE Mark approval in the EU and other countries, with over 1,000 procedures performed by more than 30 physicians in 11 countries.
• LockeT is a suture retention device for wound healing, distributing suture tension over a larger area, temporarily securing sutures, aiding in locating and removing sutures efficiently, and promoting hemostasis.
• LockeT is a sterile Class I product registered with the FDA in February 2023 and received CE Mark approval in April 2025, enabling sales in the EU, Switzerland, and Turkey.
• Catheter Precision formed subsidiaries Cardionomix, Inc. (82% owned) and KardioNav, Inc. (57% owned) in 2025 to acquire and develop additional cardiac-related technologies.
• Cardionomix acquired assets related to the Cardiac Pulmonary Nerve Stimulation (CPNS) System for late-stage treatment of acute decompensated heart failure; this system is in development and not yet approved.
• KardioNav is developing technology integrating VIVO mapping IP with patents from Chelak iECG, Inc. to improve pre-ablation mapping and localization of arrhythmogenic tissue; research and development in animals and humans has begun.
• The company completed the acquisition of PeriKard, LLC in January 2025, acquiring patented pericardial access technology in development.
• Catheter Precision markets VIVO and LockeT primarily to hospitals with cardiac electrophysiology labs, with sales in the U.S. and internationally through direct and distributor channels.
• The company’s sales team has extensive electrophysiology sales experience and supports product demonstrations and training.
• VIVO software upgrades are sold as services with revenues recognized over time; product sales revenues are recognized at delivery.
• LockeT sales have increased due to contracts with hospitals demonstrating procedural efficiency and improved patient experience compared to competing closure devices.
• VIVO sales declined in the EU due to reduced sales efforts and changes in commercial leadership.
• The company has ongoing clinical studies for LockeT demonstrating safety, effectiveness, faster wound closure, earlier ambulation, and potential cost savings.
• VIVO clinical studies include a UK registry and physician-initiated research showing high accuracy and procedural success in ventricular tachycardia mapping.
• The company’s business strategy is to become a leading medical device company in cardiac electrophysiology, improving procedural outcomes and patient lives while reducing procedure time and costs.
• Catheter Precision also operates a private aviation charter business (FLYTE) as a holding company subsidiary to attract capital.
• The company faces competition from large medical device companies such as Medtronic, Abbott, Boston Scientific, and Johnson & Johnson.
• Financial snapshot as of 2025-12-31: cash and equivalents $88,000; current assets $390,000; current liabilities $3,907,000; current ratio 0.1; cash ratio 1.3.
• Revenue for Q3 2024 was $96,000; net loss for FY 2025 was $17,183,000; basic EPS for FY 2025 was -$15.90 per share.
• The company has recurring net losses and negative cash flows from operations, with substantial doubt about its ability to continue as a going concern without additional financing.
• Recent financing includes a $1.5 million private placement in May 2025 and other equity offerings raising several million dollars.
• The company’s liquidity is constrained with current liabilities exceeding current assets and cash on hand insufficient to fund operations beyond the near term without new capital.
• Recent acquisitions and asset purchases have been accounted for as in-process research and development expenses.
• The company’s CEO and affiliates hold minority stakes in subsidiaries Cardionomix and KardioNav.
• The company’s products have regulatory clearances in the U.S. and Europe, with ongoing efforts to expand indications and market reach.
• The company’s sales outside the U.S. accounted for approximately 17-24% of sales in recent periods.
• The company has entered into long-term contracts with hospitals for LockeT, resulting in repeat orders.
• The company’s VIVO system is used as a pre-procedure planning tool to improve ablation procedure workflow and outcomes.
• The company’s LockeT device aims to improve patient comfort, reduce hospital costs, and enable same-day discharge.
• The company’s research and development includes development of VIVO generation 3 with expanded indications and improved usability.
• The company’s financial disclosures are summarized from latest SEC filings and provided for informational purposes only.